SIL declares profit from operations growth as +6% vs previous year

Mumbai: Sanofi India Limited has announced its financial results for the quarter ended June 30, 2025.

The Company recorded a 9% decline in net sales on a comparable basis of continuing business. In the Domestic market, the successful launch of Soliqua, its diabetes treatment for the premix segment, continues to gain momentum, reinforcing the company's comprehensive diabetes portfolio. Toujeo maintained strong performance with high single-digit growth.

The company's strategic partnerships in Cardiovascular (CV) and Central Nervous System (CNS) segments have established a solid foundation, meeting expectations for market reach expansion and business acceleration.

Export sales were affected by non-recurring CHC product sales from 2024 and the planned discontinuation of the Zentiva portfolio.

For the year-to-date period ended June 2025, the Company achieved a 6% increase in operating profit.

Rachid Ayari, Whole Time Director and Chief Financial Officer said, "During this transformative year for our company, our insulin portfolio has demonstrated robust growth, led by Toujeo and the successful introduction of Soliqua - our premium diabetes solution for the premix segment. Our strategic partnerships have effectively expanded our reach to healthcare professionals in both CV (Cardiovascular) and CNS (Central Nervous System) therapeutic areas, meeting our planned objectives. Moving forward, we remain committed to enhancing operational efficiency while broadening access to both our established products and innovative therapies across India."

Read also: Sanofi India ropes in Sudipta Chakraborty as Head of Legal, India